Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03864601 · ClinicalTrials.gov registry record · Phase 1
A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03864601: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT03864601 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03864601, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the absorption, the metabolic pathways, the route and rate of elimination, and total recovery of 14C-JNJ-56136379 and/or total drug derived radioactivity in healthy male adult participants after administration of a single oral dose of 14C-JNJ-56136379.
Primary Outcome
Ratio of JNJ-56136379 concentration (plasma) and total radioactivity (plasma) for maximum observed plasma concentration (Cmax) will be assessed.
Interventions
- DRUG 14C-JNJ-56136379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-04-09 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 1 |
What the finished NCT03864601 record still lists
NCT03864601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which 14C-JNJ-56136379 is the first listed.
NCT03864601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03864601 about?
NCT03864601 is a clinical study titled "A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants". The purpose of this study is to investigate the absorption, the metabolic pathways, the route and rate of elimination, and total recovery of 14C-JNJ-56136379 and/or total drug derived radioactivity in healthy male adult participants after administration of a single oral dose of 14C-JNJ-56136379.
What is the current status of trial NCT03864601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-04-09. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT03864601?
The interventions under investigation include: 14C-JNJ-56136379 (DRUG).
Who is sponsoring clinical trial NCT03864601?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03864601's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI